OLS : Record

RECORD NUMBER: 35 OF 116

Main Title Economic impact and regulatory flexibility analysis of proposed effluent guidelines for the pharmaceutical manufacturing industry {Microfiche} final report.
CORP Author Environmental Protection Agency, Washington, DC. Engineering and Analysis Div.
Publisher U.S. Environmental Protection Agency, Office of Water, Office of Science and Technology, Engineering and Analysis Division,
Place Published Washington, DC :
Year Published 1995
Report Number EPA/821/R-95/018
Stock Number PB95-219010
OCLC Number 49505605
Subjects Drug industry; Water pollution control; Economic impact; Waste water treatment; Industrial waste treatment; Facilities management; Operation and maintenance; Chemical effluents; Water pollution standards; Standards compliance; Pollution regulations; Requirements; Water pollution economics; Cost analysis; Employment; Prices; Profits; Closures; Small businesses; Economic analysis; Market analysis; Pharmaceutical manufacturing; Regulatory Flexibility Act
Subject Added Ent Effluent quality--Standards--Compliance costs; Pharmaceutical industry--United States--Environmental aspects
Internet Access
Description Access URL
http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=2000WPI9.txt
Holdings
Library   Call Number Additional Info Location Date Modified
ERBD PB95-219010 NERL/ESD-LV Library/Las Vegas,NV 04/05/2002
NTIS PB95-219010 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 01/01/1988
Collation 1 v. (various pagings) : ill. ; 28 cm.
Abstract The economic impact analysis (EIA) examines compliance costs and economic impacts resulting from the U.S. Environmental Protection Agency's (EPA's) proposed revisions to effluent guidelines for the U.S. pharmaceutical industry. The EIA estimates the economic effects of compliance with the proposed regulation in terms of annualized costs; facility closures; changes in rate of return on assets and the interest coverage ratio at the firm level; and profitability effects at the firm level. In addition, impacts on employment and affected communities, foreign trade, specific demographic groups, and new sources also are considered. Finally, a Regulatory Flexibility Analysis detailing the impacts on small businesses within the pharmaceutical industry is included in the EIA.
Notes "February 1995." "EPA 821-R-95-018"--Cover. Includes bibliographical references. Microfiche.
Corporate Au Added Ent United States. Environmental Protection Agency. Office of Science and Technology. Engineering and Analysis Division.
PUB Date Free Form 1995.
NTIS Prices PC A14/MF A03
BIB Level m
OCLC Time Stamp 20020402174615
Cataloging Source OCLC/T
Language eng
Origin OCLC
Type MERGE
OCLC Rec Leader 01245nam 2200253Ka 45020